{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:48:16Z","timestamp":1791726496187,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijid.2022.06.046","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:13:54Z","timestamp":1656893634000},"page":"529-530","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Nucleocapsid as a next-generation COVID-19 vaccine candidate"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3940-6329","authenticated-orcid":false,"given":"Bryan","family":"Oronsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-7320","authenticated-orcid":false,"given":"Christopher","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-6917","authenticated-orcid":false,"given":"Scott","family":"Caroen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Hedjran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4661-8378","authenticated-orcid":false,"given":"Ana","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Prokopenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.06.046_bib0001","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1016\/S2666-5247(21)00358-X","article-title":"Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults","volume":"3","author":"Ahn","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2022.06.046_bib0002","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41591-022-01699-1","article-title":"Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England","volume":"28","author":"Andrews","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2022.06.046_bib0003","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.cell.2020.10.049","article-title":"Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer","volume":"183","author":"Avanzato","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2022.06.046_bib0004","doi-asserted-by":"crossref","first-page":"eabn8014","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","volume":"7","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ijid.2022.06.046_bib0005","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3390\/vaccines10050798","article-title":"Immunogenicity and safety of homologous and heterologous prime-boost immunization with COVID-19 vaccine: systematic review and meta-analysis","volume":"10","author":"Cheng","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijid.2022.06.046_bib0006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.vaccine.2021.11.051","article-title":"Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection","volume":"40","author":"Dinc","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2022.06.046_bib0007","doi-asserted-by":"crossref","first-page":"e00620","DOI":"10.1128\/JVI.00647-20","article-title":"The nucleocapsid protein of SARS-CoV-2: a target for vaccine development","volume":"94","author":"Dutta","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.ijid.2022.06.046_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ijid.2022.06.046_bib0009","doi-asserted-by":"crossref","first-page":"e815","DOI":"10.1093\/cid\/ciab072","article-title":"Intractable coronavirus disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study","volume":"73","author":"Hensley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.046_bib0010","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/s41586-020-2550-z","article-title":"SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls","volume":"584","author":"Le Bert","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2022.06.046_bib0011","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4049\/jimmunol.177.2.831","article-title":"Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination","volume":"177","author":"Masopust","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2022.06.046_bib0012","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijid.2022.06.046_bib0013","first-page":"1","article-title":"An update on host immunity correlates and prospects of re-infection in COVID-19","author":"Negi","year":"2021","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.ijid.2022.06.046_bib0014","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.immuni.2021.04.009","article-title":"CD8\u00a0+\u00a0T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity","volume":"54","author":"Nguyen","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.ijid.2022.06.046_bib0015","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1093\/infdis\/jiab622","article-title":"Yearlong COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B-cell depletion","volume":"225","author":"Nussenblatt","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2022.06.046_bib0016","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-5699(00)01612-1","article-title":"The prime-boost strategy: exciting prospects for improved vaccination","volume":"21","author":"Ramshaw","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/j.ijid.2022.06.046_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585354","article-title":"A review of the progress and challenges of developing a vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijid.2022.06.046_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0268434","article-title":"Immunization with SARS-CoV-2 nucleocapsid protein triggers a pulmonary immune response in rats","volume":"17","author":"Silva","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijid.2022.06.046_bib0019","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211491","article-title":"Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs","volume":"41","author":"Thura","year":"2021","journal-title":"Biosci Rep"},{"key":"10.1016\/j.ijid.2022.06.046_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103355","article-title":"Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: a consecutive case series","volume":"67","author":"Truong","year":"2021","journal-title":"EBioMedicine"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T14:34:24Z","timestamp":1715438064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222003794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":20,"alternative-id":["S1201971222003794"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.046","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nucleocapsid as a next-generation COVID-19 vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.06.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}